Rapport Therapeutics (RAPP) Operating Income (2023 - 2026)
Rapport Therapeutics (RAPP) has 4 years of Operating Income data on record, last reported at -$24.2 million in Q1 2026.
- On a quarterly basis, Operating Income rose 10.67% to -$24.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$122.2 million, a 31.31% decrease, with the full-year FY2025 number at -$125.1 million, down 50.62% from a year prior.
- Operating Income reached -$24.2 million in Q1 2026 per RAPP's latest filing, up from -$38.5 million in the prior quarter.
- Over the last five years, Operating Income for RAPP hit a ceiling of -$6.6 million in Q2 2023 and a floor of -$38.5 million in Q4 2025.
- A 4-year average of -$21.9 million and a median of -$22.6 million in 2024 define the central range for Operating Income.
- Peak YoY movement for Operating Income: plummeted 213.73% in 2024, then grew 10.67% in 2026.
- Tracing RAPP's Operating Income over 4 years: stood at -$14.8 million in 2023, then tumbled by 58.99% to -$23.5 million in 2024, then plummeted by 63.72% to -$38.5 million in 2025, then surged by 37.12% to -$24.2 million in 2026.
- Business Quant data shows Operating Income for RAPP at -$24.2 million in Q1 2026, -$38.5 million in Q4 2025, and -$30.0 million in Q3 2025.